SLE Clinical Trial
Official title:
Studying of New Signaling Pathway Targeting Systemic Lupus Erythematosus
Systemic lupus erythematosus is inflammatory autoimmune disease that affects over one million people in the United States. It has a higher prevalence and incidence rate among women compared with men, and among African Americans compared with Caucasians. Despite advances in treatment, standardized mortality rates in SLE remain three times higher than in the general population. The risk of mortality is significantly increased because of renal disease, cardiovascular disease, and infection.The etiology of SLE is multifactorial, with genetic predisposition, environmental factors and epigenetic alterations are involved. However, the molecular mechanisms underlying this systemic autoimmune response remain largely unknown. A key issue in the pathogenesis of lupus is how intracellular antigens become exposed and targeted by the immune system.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | April 2021 |
Est. primary completion date | December 2020 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - SLE diagnosed patients between (18- 60) years old will be enrolled. Exclusion Criteria: - Patients with known pre-existing immunological disorders. - Patients with known pre-existing infection. - clinical diagnosis of cancer. - patients diagnosed with concomitant acute myocardial infarction. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF. The NLRP3 inflammasome functions as a dr — View Citation
Dang Y, Wang X, Hao Y, Zhang X, Zhao S, Ma J, Qin Y, Chen ZJ. MicroRNA-379-5p is associate with biochemical premature ovarian insufficiency through PARP1 and XRCC6. Cell Death Dis. 2018 Jan 24;9(2):106. doi: 10.1038/s41419-017-0163-8. — View Citation
Li J, Xue J, Wang D, Dai X, Sun Q, Xiao T, Wu L, Xia H, Mostofa G, Chen X, Wei Y, Chen F, Quamruzzaman Q, Zhang A, Liu Q. Regulation of gasdermin D by miR-379-5p is involved in arsenite-induced activation of hepatic stellate cells and in fibrosis via secr — View Citation
Magna M, Pisetsky DS. The Role of Cell Death in the Pathogenesis of SLE: Is Pyroptosis the Missing Link? Scand J Immunol. 2015 Sep;82(3):218-24. doi: 10.1111/sji.12335. Review. — View Citation
Shi G, Abbott KN, Wu W, Salter RD, Keyel PA. Dnase1L3 Regulates Inflammasome-Dependent Cytokine Secretion. Front Immunol. 2017 May 8;8:522. doi: 10.3389/fimmu.2017.00522. eCollection 2017. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | determination of the expression levels of GSDMD, NF-kB and miR-379-5p in SLE group and Control group | GSDMD, NF-kB and miR-379-5p expression levels will be measured using quantitative real time PCR | 6 months | |
Primary | detection of the relationship between oxidative stress and pyroptosis | correlation between oxidative stress and pyroptosis and detect if there is relationship between them | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05479071 -
Relation of Antibodies Against Oxidized Low Density Lipoproteins to Disease Activity and Cardiovascular Affection in Systemic Lupus.
|
||
Completed |
NCT02240888 -
Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response
|
N/A | |
Active, not recruiting |
NCT05748925 -
Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
|
Phase 4 | |
Not yet recruiting |
NCT04517240 -
A Study on Protein Losing Enteropathy In Systemic Lupus Erythematosus
|
||
Completed |
NCT00710021 -
Vitamin D3 in Systemic Lupus Erythematosus
|
Phase 2 | |
Terminated |
NCT01946880 -
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
|
Phase 2 | |
Recruiting |
NCT06445127 -
Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging)
|
N/A | |
Active, not recruiting |
NCT04018222 -
Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic
|
||
Completed |
NCT03240536 -
Choosing Tests Wisely in Rheumatology
|
N/A | |
Completed |
NCT04368299 -
Telemedicine for Follow-up of Systemic Lupus Erythematosus
|
N/A | |
Active, not recruiting |
NCT04037293 -
Premature Atherosclerosis in Systemic Lupus Erythematosus
|
||
Not yet recruiting |
NCT04234633 -
Effect of Gender on Clinical Presentation of SLE ِAt Assiut University Hospitals
|
||
Completed |
NCT01207297 -
Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis
|
Phase 1 | |
Terminated |
NCT00152555 -
Physical Therapy for Systemic Lupus Erythematosus (SLE)
|
N/A | |
Recruiting |
NCT05822219 -
Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases
|
N/A | |
Completed |
NCT04806113 -
COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases
|
Phase 3 | |
Recruiting |
NCT05966480 -
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT03155477 -
Effect Of Curcuma Xanthorrhiza and Vitamin D3 Supplementation in SLE Patients With Hypovitamin D
|
N/A | |
Recruiting |
NCT05342285 -
Flow Mediated Dilation in Association With Hyperuricemia
|
||
Enrolling by invitation |
NCT03144063 -
Improving the Assessment of SLE Disease Activity
|
N/A |